Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
8
×
national blog main
new york top stories
fda
national top stories
new york blog main
biotech
boston blog main
boston top stories
san diego blog main
san diego top stories
san francisco top stories
europe top stories
indiana blog main
indiana top stories
national
san francisco blog main
akcea therapeutics
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
europe blog main
gene therapy
inotersen
new york
parkinson's disease
patisiran
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
What
fda
8
×
patients
8
×
drug
approved
disease
friday
medicine
ago
alnylam
daily
gets
help
new
nod
parkinson’s
therapy
time
acorda
add
akcea
amyloidosis
approval
approve
aren’t
atrophy
attr
available
awaits
battle
bid
bio
biological
boehringer
called
cancer
carbidopa
combination
control
cope
crossed
Language
unset
Current search:
fda
×
patients
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision